iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600
Yahoo Finance · Apr 24, 2026 · iBio, Inc. Common Stock (IBIO)
iBio Inc. (NASDAQ:IBIO) is one of the best NASDAQ growth stocks to buy and hold forever. On April 8, iBio received regulatory clearance and ethics approval to initiate its first-in-human Phase 1 clinical trial of IBIO-600 in Australia. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of the therapy in overweight […]
Not investment advice. Cached headline, not a full reprint.